Immunotherapy
News from the FDA/CDC
FDA approves new indications for pembrolizumab
Conference Coverage
Personalized cancer vaccine may enhance checkpoint inhibitor activity
Conference Coverage
New registry focuses on rheumatic immune-related AEs of cancer therapy
Data from the German TRheuMa registry suggest these events are generally mild or moderate, verifiable by CRP level and imaging (but not...
News
FDA approves immunotherapy combo for liver cancer
Conference Coverage
Cancer increase observed in modern era of MS drugs
WEST PALM BEACH, FLA. – The increased incidence is observed post 1996; the risk is nevertheless called small.
From the Journals
Tumor neoantigenicity metric improves prediction of response to immunotherapy
A new scoring system can predict response to immunotherapy in patients with melanoma, lung cancer, and kidney cancer.
Video
Experts break down latest CAR T-cell advances in lymphoma
ORLANDO – An expert panel of physicians discusses the latest research on CAR T-cell therapy in lymphoma, presented at the 2019 annual meeting of...
From the Journals
New toxicity subscale measures QOL in cancer patients on checkpoint inhibitors
With further validation, the instrument could become an important tool for evaluation of treatment-related toxicity.
Conference Coverage
CAR T cells produce complete responses in T-cell malignancies
ORLANDO – There were no cases of severe cytokine release syndrome or severe neurotoxicity reported with the anti-CD5 chimeric antigen receptor T...
Conference Coverage
CAR T-cell therapy advances in CLL
ORLANDO – The safety and clinical activity of the CD19-directed CAR T-cell agent justifies moving forward with phase 2 investigation, researchers...
Conference Coverage
Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patients
ORLANDO – All 10 patients responded to anti-BCMA CAR T-cell therapy, including 3 patients who had previously failed BCMA-directed therapy.